Patent ID: 9108933
Filing Date: 2015-08-18
Classification: A61K,A61P,C07D

Abstract:
1. A method of treating a c-Met associated cancer in a subject, comprising administering to the subject an effective amount of a compound represented by formula (XVIII): or a tautomer or pharmaceutically acceptable salt thereof, wherein: R R R i) one substituent selected from nitro, cyano, a haloalkoxy, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, hydroxylalkyl, alkoxyalkyl, guanadino, —NR ii) two to five substituents selected from the group consisting of an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, hydroxyalkyl, alkoxyalkyl, —F, —Br, —I, cyano, nitro, guanadino, a haloalkyl, a heteroalkyl, —NR R R R R R p, for each occurrence, is, independently, 0, 1 or 2; n is zero of an interger from 1 to 4; and m, for each occurrence, is independently, 1, 2, 3, or 4, wherein the c-Met associated cancer has developed a resistance to treatment with a tyrosine kinase inhibitor.